New to online subscriber access? Create your account.
Log In
About Us
RSS
Contact Us
Help
E-Letters

FREE PREVIEW | Subscribers get full access to this article: Free Trial » Subscribe »

Achaogen Raises $56M In Series C Round To Advance Next-Generation Antibiotic Programs

By The Pink Sheet Daily / Email the Author / “The Pink Sheet” DAILY Apr. 7, 2010
Word Count: 705 / Article # 14100407003

Executive Summary

Achaogen turns to VC backers to advance its lead compound into Phase II trials for complicated urinary tract infections.

Purchase this Article

$50.00 Buy Now

For $50.00, purchase this 705-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

+ Show All | – Hide All

Offers & Events

Related Deals: 1

Strategic Transactions

Click a deal headline for more information
Achaogen closes $26.5mm Series B round

Topics Covered in this Article

Click a keyword for related articles.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Achaogen Raises $56M In Series C Round To Advance Next-Generation Antibiotic Programs

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to “The Pink Sheet” DAILY will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel